PolyQ fibrillation in the cell nucleus: who's bad?

Trends in Cell Biology

Volumn 19, Issue 12, 2009, Pages 685-691

  von Mikecz, Anna ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HUNTINGTIN; POLYGLUTAMINE; PROTEASOME; UBIQUITIN;

AGING; ARTICLE; CELL NUCLEUS; CELL NUCLEUS INCLUSION BODY; DEGENERATIVE DISEASE; DENTATORUBROPALLIDOLUYSIAN ATROPHY; EXON; GENE EXPRESSION; HUMAN; HUNTINGTON CHOREA; KENNEDY DISEASE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN AGGREGATION; PROTEIN DEGRADATION; PROTEIN FOLDING; PROTEIN MOTIF; SPINOCEREBELLAR DEGENERATION; TRINUCLEOTIDE REPEAT; XENOBIOTIC STRESS;

ANIMALS; CELL NUCLEUS; GENE EXPRESSION REGULATION; HUMANS; NUCLEAR PROTEINS; PEPTIDES; PROTEIN FOLDING;

EID: 70449780852     PISSN: 09628924     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tcb.2009.09.001     Document Type: Article

References (76)

1. Orr H.T., and Zoghbi H.Y. Trinucleotide repeat disorders. Annu. Rev. Neurosci. 30 (2007) 575-621
2. Williams A.J., and Paulson H.L. Polyglutamine neurodegeneration: protein misfolding revisited. Trends Neurosc. 31 (2008) 521-528
3. DiFiglia M., et al. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 277 (1997) 1990-1993
4. Davies S.W., et al. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 90 (1997) 537-548
5. Nagai Y., et al. A toxic monomeric conformer of the polyglutamine protein. Nat. Struct. Mol. Biol. 14 (2007) 332-340
6. Kayed R., et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300 (2003) 486-489
7. Nekooki-Machida Y., et al. Distinct conformations of in vitro and in vivo amyloids of huntingtin-exon 1 show different cytotoxicity. Proc. Natl. Acad. Sci. USA 106 (2009) 9679-9684
8. Saudou F., et al. Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell 95 (1998) 55-66
9. Kopito R.R. Aggresomes, inclusion bodies and protein aggregation. Trends Cell Biol. 10 (2000) 524-530
10. Taylor J.P., et al. Aggresomes protect cells by enhancing the degradation of toxic polyglutamine-containing protein. Hum. Mol. Genet. 12 (2003) 749-757
11. Arrasate M., et al. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 431 (2004) 805-810
12. Orr H.T. Neurodegenerative disease: neuron protection agency. Nature 431 (2004) 747-748
13. Chen M., et al. Nuclear polyglutamine-containing protein aggregates as active proteolytic centers. J. Cell Biol. 180 (2008) 697-704
14. Bett J.S., et al. The ubiquitin-proteasome reporter GFPu does not accumulate in neurons of the R6/2 transgenic mouse model of Huntington's disease. PLoS ONE 4 (2009) e5128
15. Pratt G., and Rechsteiner M. Proteasomes cleave at multiple sites within polyglutamine tracts. J. Biol. Chem. 19 (2008) 12919-12925
16. Treusch S., et al. Amyloid deposits: protection against toxic protein species?. Cell Cycle 8 (2009) 1668-1674
17. Faux N.G., et al. Functional insights from the distribution and role of homopeptide repeat-containing proteins. Genome Res. 15 (2005) 537-551
18. Gerber H.P., et al. Transcriptional activation modulated by homopolymeric glutamine and proline stretches. Science 263 (1994) 808-811
19. Courey A.J., et al. Synergistic activation by the glutamine-rich domains of human transcription factor Sp1. Cell 59 (1989) 827-836
20. Canettieri G., et al. Attenuation of a phosphorylation-dependent activator by an HDAC-PP1 complex. Nat. Struct. Biol. 10 (2003) 175-181
21. Lin C.H., et al. A small domain of CBP/p300 binds diverse proteins: solution structure and functional studies. Mol. Cell 8 (2001) 581-590
22. Kay B.K., et al. The importance of being proline: the interaction of proline-rich motifs in signaling proteins with their cognate domains. FASEB J. 14 (2000) 231-241
23. Bhattacharyya R.P., et al. Domains, motifs and scaffolds: the role of modular interactions in the evolution and wiring of cell signaling circuits. Annu. Rev. Biochem. 75 (2006) 655-680
24. Kiel C., et al. Analyzing protein interaction networks using structural information. Annu. Rev. Biochem. 77 (2008) 415-441
25. Kuriyan J., and Eisenberg D. The origin of protein interactions and allostery in colocalization. Nature 450 (2007) 983-990
26. Misteli T. Beyond the sequence: cellular organization of genome function. Cell 128 (2007) 787-800
27. Trinkle-Mulkahy L., and Lamond A.I. Towards a high-resolution view of nuclear dynamics. Science 318 (2007) 1402-1407
28. McNally J.G., et al. The glucocorticoid receptor: rapid exchange with regulatory sites in living cells. Science 287 (2000) 1262-1265
29. Klokk T.I., et al. Ligand-specific dynamics of the androgen receptor at its response element in living cells. Mol. Cell Biol. 27 (2007) 1823-1843
30. Hoogstraten D., et al. Rapid switching of TFIIH between RNA polymerase I and II transcription and DANN repair in vivo. Mol. Cell. 10 (2002) 1163-1174
31. Chen D., et al. TBP dynamics in living human cells: constitutive association of TBP with mitotic chromosomes. Mol. Biol. Cell. 13 (2002) 276-284
32. Phair R.D., et al. Measurement of dynamic protein binding to chromatin in vivo using photobleaching microscopy. Methods Enzymol. 375 (2004) 393-414
33. Mayr B.M., et al. Glutamine rich and basic region/leucine zipper (bZIP) domains stabilize cAMP-response element-binding protein (CREB) binding to chromatin. J. Biol. Chem. 280 (2005) 15103-15110
34. Darzacq X., et al. In vivo dynamics of RNA polymerase II transcription. Nat. Struct. Mol. Biol. 14 (2007) 796-806
35. Klein F.A., et al. Pathogenic and non-pathogenic polyglutamine tracts have similar structural properties: towards a length-dependent toxicity gradient. J. Mol. Biol. 371 (2007) 235-244
36. Chen S., et al. Polyglutamine aggregation behavior in vitro supports a recruitment mechanism of cytotoxicity. J. Mol. Biol. 311 (2001) 173-182
37. Bennett M., et al. Inaugural article: a linear lattice model for polyglutamine in CAG-expansion diseases. Proc. Natl. Acad. Sci. USA 99 (2002) 11634-11639
38. Masino L., et al. Solution structure of polyglutamine tracts in GST-polyglutamine fusion proteins. FEBS Lett. 513 (2002) 267-272
39. Scherzinger E., et al. Self-assembly of polyglutamine-containing huntingtin fragments into amyloid-like fibrils: implications for Huntington's disease pathology. Proc. Natl. Acad. Sci. USA 96 (1999) 4604-4609
40. Schwartz A.L., and Ciechanover A. Targeting proteins for destruction by the ubiquitin system: implications for human pathobiology. Annu. Rev. Pharmacol. Toxicol. 49 (2009) 73-96
41. McGowan D.P., et al. Amyloid-like inclusions in Huntington's disease. Neuroscience 100 (2000) 677-680
42. Ross C.A., et al. Polyglutamine fibrillogenesis: the pathway unfolds. Proc. Natl. Acad. Sci. USA 100 (2003) 1-3
43. Belotti V., and Chiti F. Amyloidogenesis in its biological environment: challenging a fundamental issue in protein misfolding diseases. Cur. Opin. Struct. Biol. 18 (2008) 771-779
44. Robertson A.L., et al. The structural impact of a polyglutamine tract Is location-dependent. Biophys. J. 15 (2008) 5922-5930
45. Thakur A.K., et al. Polyglutamine disruption of the huntingtin exon 1 N terminus triggers a complex aggregation mechanism. Nat. Struct. Mol. Biol. 16 (2009) 380-389
46. Lee C.C., et al. Reconsidering the mechanism of polyglutamine peptide aggregation. Biochemistry 46 (2007) 12810-12820
47. Bernacki J.P., and Murphy R.M. Model discrimination and mechanistic interpretation of kinetic data in protein aggregation studies. Biophys. J. 96 (2009) 2871-2887
48. Vitalis A., et al. Thermodynamics of β-sheet formation in polyglutamine. Biophys. J. 97 (2009) 303-311
49. Jellinger K.A. Neuropathological aspects of Alzheimer's disease. Parkinson's disease and frontotemporal dementia. Neurodegener. Dis. 5 (2008) 118-121
50. Chiti F., and Dobson C.M. Protein misfolding, functional amyloid and human disease. Annu. Rev. Biochem. 75 (2006) 333-366
51. Frid P., et al. Congo red and protein aggregation in neurodegenerative diseases. Brain Res. Rev. 53 (2006) 135-160
52. Nilsson K.P. Small organic probes as amyloid specific ligands - past and recent molecular scaffolds. FEBS Lett. 583 (2009) 2593-2599
53. Chen M., and von Mikecz A. Formation of nucleoplasmic protein aggregates impairs nuclear function in response to SiO2 nanoparticles. Exp. Cell Res. 305 (2005) 51-62
54. Sanchez I., et al. Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders. Nature 421 (2003) 373-379
55. Fowler D.M., et al. Functional amyloid: from bacteria to humans. Trends Biochem. Sci. 32 (2007) 217-224
56. Fowler D.M., et al. Functional amyloid formation within mammalian tissue. PLoS Biol. 4 (2006) e6
57. Yamada S., et al. Archaeal proteasomes effectively degrade aggregation-prone proteins and reduce cellular toxicities in mammalian cells. J. Biol. Chem. 281 (2006) 23842-23851
58. Rousseau E., et al. Misfolding of proteins with a polyglutamine expansion is facilitated by proteasomal chaperones. J. Biol. Chem. 284 (2009) 1917-1929
59. Kirkwood T.B.L. Understanding the odd science of aging. Cell 120 (2005) 437-447
60. Steers N.J., et al. HIV type 1 gag p24 alters the composition of immunoproteasomes and affects antigen presentation. J. Virol. 83 (2009) 7049-7061
61. Zhou H.X., et al. Macromolecular crowding and confinement: biochemical, biophysical and potential physiological consequences. Annu. Rev. Biophys. 37 (2008) 375-397
62. Chen M., et al. Subcellular recruitment of fibrillarin to nucleoplasmic proteasomes: implications for processing of a nucleolar autoantigen. Mol. Biol. Cell 13 (2002) 3576-3587
63. Donaldson K.M., et al. Ubiquitin-mediated sequestration of normal cellular proteins into polyglutamine aggregates. Proc. Natl. Acad. Sci. USA 100 (2003) 8892-8897
64. Helmlinger D., et al. Transcriptional alterations and chromatin remodeling in polyglutamine diseases. Trends Genet. 22 (2006) 562-570
65. Todi S.V., et al. Ubiquitination directly enhances activity of the deubiquitinating enzyme ataxin-3. EMBO J. 28 (2009) 372-382
66. Prahlad V., and Morimoto R.I. Integrating the stress response: lessons for neurodegenerative diseases from C. elegans. Trends Cell Biol. 19 (2009) 52-61
67. Marsh J.L., et al. Animal models of polyglutamine diseases and therapeutic approaches. J. Biol. Chem. 284 (2009) 7431-7435
68. Chiti F., et al. Rationalization of the effects of mutations on peptide and protein aggregation rates. Nature 424 (2003) 805-808
69. Tartaglia G.G., et al. Prediction of aggregation-prone regions in structured proteins. J. Mol. Biol. 380 (2008) 425-436
70. Sigurdson C.J., et al. Prion strain discrimination using luminescent conjugated polymers. Nat. Methods. 4 (2007) 1023-1030
71. Kvam E., et al. Conformational targeting of fibrillar polyglutamine proteins in live cells escalates aggregation and cytotoxicity. PLoS ONE 4 (2009) e5727
72. Legleiter J., et al. Monoclonal antibodies recognize distinct conformational epitopes formed by polyglutamine in a mutant huntingtin fragment. J. Biol. Chem. 284 (2009) 21647-21658
73. Howarth J.L., et al. HSP70 interacting protein prevents the accumulation of inclusions in polyglutamine disease. J. Neurochem. 108 (2009) 945-951
74. Morimoto R. Proteotoxic stress and inducible chaperone networks in neurodegenerative disease and aging. Genes Dev. 22 (2008) 1427-1438
75. Cashikar A.G., et al. A chaperone pathway in protein disaggregation. J. Biol. Chem. 280 (2005) 23869-23875
76. Kim S., et al. Polyglutamine protein aggregates are dynamic. Nat. Cell Biol. 4 (2002) 826-831